{
    "name": "azithromycin ophthalmic",
    "comment": "Rx",
    "other_names": [
        "AzaSite"
    ],
    "classes": [
        "Macrolides",
        "Ophthalmic"
    ],
    "source": "https://reference.medscape.com/drug/azasite-azithromycin-ophthalmic-343574",
    "pregnancy": {
        "common": [
            "No clinical studies conducted in pregnant women; therapy should not be administered during pregnancy unless expected benefit to mother outweighs potential risk to fetus"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Studies conducted with azithromycin in rats and mice at a dose of 200 mg/kg/d were associated with moderate maternal toxicity; this dose is estimated to be approximately 5000 times maximum (2 mg) human ocular daily dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "The safety in breastfed infants of mothers who received therapy has not been established; following systemic administration, it is unknown whether azithromycin is excreted in human milk; because many drugs are excreted in human milk, caution should be exercised when azithromycin is administered to a nursing woman"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Known hypersensitivity to azithromycin or erythromycin",
                "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Stevens Johnson Syndrome and toxic epidermal necrolysis have been reported; although rare, fatalities have been reported",
                "If superinfection occurs or if clinical improvement not noted within 7 days, discontinue use and institute appropriate therapy; whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and where appropriate, fluorescein staining",
                "Therapy may result in overgrowth of nonsusceptible organisms including fungi",
                "Avoid contact lens wear during therapy of S/S of bacterial conjunctivitis",
                "Do not administer systemically; inject SC; or apply directly into anterior eye chamber"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Eye irritation",
            "percent": "1-2"
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "Contact dermatitis",
            "percent": null
        },
        {
            "name": "Corneal erosion",
            "percent": null
        },
        {
            "name": "Dry eye",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Dygeusia",
            "percent": null
        },
        {
            "name": "Nasal congestion",
            "percent": null
        },
        {
            "name": "Ocular discharge",
            "percent": null
        },
        {
            "name": "Punctate keratitis",
            "percent": null
        },
        {
            "name": "Sinusitis",
            "percent": null
        }
    ]
}